



182/1634

Electronic Filing System (EFS) Data
Electronic Patent Application Submission
USPTO Use Only

EFS ID: 65435

Application ID: 09741550



Title of Invention: USING OVEREXPRESSION OF
LAMININ ALPHA 4 SUBUNIT AS A
DIAGNOSTIC AND PROGNOSTIC
INDICATOR OF MALIGNANT
TUMORS

First Named Inventor: Julia LJUBIMOVA

Domestic/Foreign Application: Domestic Application

Filing Date: 2000-12-19

Effective Receipt Date: 2004-07-28

Submission Type: BIO Sequence Filing


Filing Type:

Confirmation number: 6437

Attorney Docket Number: 356830.00300




Total Fees Authorized:


Digital Certificate Holder: cn=Stefan James Kirchanski,ou=Registered Attorneys,ou=Patent and
Trademark Office,ou=Department of Commerce,o=U.S. Government,c=US
Certificate Message Digest: ce2a0a90a6d1b788b9391a713f8c610a00baa5b8

**TRANSMITTAL**

Electronic Version v1.1

Stylesheet Version v1.1.0

Title of Invention	USING OVEREXPRESSION OF LAMININ ALPHA 4 SUBUNIT AS A DIAGNOSTIC AND PROGNOSTIC INDICATOR OF MALIGNANT TUMORS																
<table><tr><td>Application Number:</td><td>09/741550</td><td></td></tr><tr><td>Date:</td><td colspan="2">2000-12-19</td></tr><tr><td>First Named Applicant:</td><td colspan="2">Dr. Julia LJUBIMOVA</td></tr><tr><td>Confirmation Number:</td><td colspan="2">6437</td></tr><tr><td>Attorney Docket Number:</td><td colspan="2">356830.00300</td></tr></table>			Application Number:	09/741550		Date:	2000-12-19		First Named Applicant:	Dr. Julia LJUBIMOVA		Confirmation Number:	6437		Attorney Docket Number:	356830.00300	
Application Number:	09/741550																
Date:	2000-12-19																
First Named Applicant:	Dr. Julia LJUBIMOVA																
Confirmation Number:	6437																
Attorney Docket Number:	356830.00300																
<p>I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.</p> <p>I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.</p> <table border="1"><thead><tr><th>Submitted by:</th><th>Elec. Sign.</th><th>Sign. Capacity</th></tr></thead><tbody><tr><td>Dr. Stefan James Kirchanski Registered Number: 36,568</td><td>/stefan kirchanski/</td><td>Attorney</td></tr></tbody></table>			Submitted by:	Elec. Sign.	Sign. Capacity	Dr. Stefan James Kirchanski Registered Number: 36,568	/stefan kirchanski/	Attorney									
Submitted by:	Elec. Sign.	Sign. Capacity															
Dr. Stefan James Kirchanski Registered Number: 36,568	/stefan kirchanski/	Attorney															
<table><tr><td>Documents being submitted</td><td>Files</td></tr><tr><td>us-bio-seq-trans</td><td>Arrogene_09-741550-usbios.xml</td></tr><tr><td></td><td>us-bio-seq-trans.dtd</td></tr><tr><td></td><td>us-bio-seq-trans.xsl</td></tr><tr><td>sequence-listing</td><td>arroST25.txt</td></tr></table>			Documents being submitted	Files	us-bio-seq-trans	Arrogene_09-741550-usbios.xml		us-bio-seq-trans.dtd		us-bio-seq-trans.xsl	sequence-listing	arroST25.txt					
Documents being submitted	Files																
us-bio-seq-trans	Arrogene_09-741550-usbios.xml																
	us-bio-seq-trans.dtd																
	us-bio-seq-trans.xsl																
sequence-listing	arroST25.txt																
Comments																	



AMINO ACID AND/OR NUCLEOTIDE SEQUENCE LISTING SUBMISSION

Electronic Version v13

Stylesheet Version v01

This is a request for filing the electronic Computer Readable Form copy of a sequence listing via the Electronic Filing System for a patent application under 37 CFR 1.821-1.825 instead of via one of the physical media specified in 37 CFR 1.824(c).

This communication has an attached file which is an electronic copy of the amino acid and/or nucleotide sequence listing for the previously mentioned United States patent application.

The electronic copy submitted herewith is the Computer Readable Form (CRF), as required by 1.821(e).

Any applicable fees associated with the filing of the electronic copy have been paid.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter). It may be in addition to an original CRF, filed to comply with the sequence rules.

This submission in electronic form comprises only the CRF of 37 CFR 1.821(e). I acknowledge that I am responsible for all additional requirements of amino acid and/or nucleotide sequence listing submissions as specified in 37 CFR 1.821 - 1.825.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter), and/or is in addition to an original CRF filed to comply with the sequence rules. If not made to comply with an originally filed CRF, it is identical to the sequences disclosed in the application as originally filed and/or the paper copy of the sequence listing as originally filed.

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office on the following date: 2004-07-27

Name: Stefan J. Kirchanski

Electronic Signature Mark: /Stefan Kirchanski/

Attachment description:	ST25.txt file produced by Patent In Version 3.2
Compression software used:	none